These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21434804)

  • 21. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
    Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L
    J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P; Havlícková M; Tácner J; Novotná O; Jirkovská M; Cechová D; Julák J; Sterzl I; Prokesová L
    Immunol Lett; 2008 Jan; 115(2):144-52. PubMed ID: 18160106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial.
    Wu J; Liu SZ; Dong SS; Dong XP; Zhang WL; Lu M; Li CG; Zhou JC; Fang HH; Liu Y; Liu LY; Qiu YZ; Gao Q; Zhang XM; Chen JT; Zhong X; Yin WD; Feng ZJ
    Vaccine; 2010 Aug; 28(38):6221-7. PubMed ID: 20638454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM; Aoki F; Ward BJ; McGeer A; Angel JB; Stiver G; Gorfinkel I; Shu D; White L; Lasko B; Dzongowski P; Papp K; Alexander M; Boivin G; Fries L
    Vaccine; 2011 Feb; 29(10):1921-8. PubMed ID: 21219987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
    Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2009 May; 58(19):521-4. PubMed ID: 19478718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
    Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influenza vaccine 2008-2009.
    Med Lett Drugs Ther; 2008 Oct; 50(1296):77-9. PubMed ID: 18833032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial.
    Wu J; Li W; Wang HQ; Chen JT; Lv M; Zhou JC; Liang XF; Fang HH; Liu Y; Liu LY; Wang X; Zhang WL; Zhang XM; Song LF; Qiu YZ; Li CG; Wang JZ; Wang Y; Yin WD
    J Infect Dis; 2010 Sep; 202(5):675-80. PubMed ID: 20632888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic.
    Engelhard D; Zakay-Rones Z; Shapira MY; Resnick I; Averbuch D; Grisariu S; Dray L; Djian E; Strauss-Liviatan N; Grotto I; Wolf DG; Or R
    Vaccine; 2011 Feb; 29(9):1777-82. PubMed ID: 21216315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level.
    Bracci L; Canini I; Puzelli S; Sestili P; Venditti M; Spada M; Donatelli I; Belardelli F; Proietti E
    Vaccine; 2005 Apr; 23(23):2994-3004. PubMed ID: 15811645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Live attenuated influenza vaccine in children.
    Ambrose CS; Walker RE; Connor EM
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):206-12. PubMed ID: 17055372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients.
    Bickel M; von Hentig N; Wieters I; Khaykin P; Nisius G; Haberl A; Stephan C; Herrmann E; Doerr HW; Brodt HR; Allwinn R
    Clin Infect Dis; 2011 Jan; 52(1):122-7. PubMed ID: 21148530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influenza vaccine immunology.
    Dormitzer PR; Galli G; Castellino F; Golding H; Khurana S; Del Giudice G; Rappuoli R
    Immunol Rev; 2011 Jan; 239(1):167-77. PubMed ID: 21198671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pandemic influenza vaccine policy--considering the early evidence.
    Neuzil KM
    N Engl J Med; 2009 Dec; 361(25):e59. PubMed ID: 19745213
    [No Abstract]   [Full Text] [Related]  

  • 38. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
    Hancock K; Veguilla V; Lu X; Zhong W; Butler EN; Sun H; Liu F; Dong L; DeVos JR; Gargiullo PM; Brammer TL; Cox NJ; Tumpey TM; Katz JM
    N Engl J Med; 2009 Nov; 361(20):1945-52. PubMed ID: 19745214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.
    Esposito S; Tagliaferri L; Daleno C; Valzano A; Picciolli I; Tel F; Prunotto G; Serra D; Galeone C; Plebani A; Principi N
    Vaccine; 2011 Feb; 29(8):1677-82. PubMed ID: 21199699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
    Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
    Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.